Today is all about Merck Serono. Two substances that were in Serono’s pipeline in phase 1, “JNK inhibitor” and “MMP-12 inhibitor” are no longer there. I’ve removed them from the list. The Serono compound “Osteopontin” has moved from pre-clinical to phase 1. The best news is that Merck Serono has added a substance, Atacicept, to their pipeline in phase 2. It is a collaboration with ZymoGenetics. The drug was formerly known as TACI-Ig. It is also being tested for lupus and RA.